Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA – The Lancet

by

  1. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet
  2. American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium PR Newswire
  3. American Diabetes Association Highlights New Developments in Diabetes Technology Pharmacy Times
  4. American Diabetes Association presentation highlights innovations in technology for diabetic eye condition Ophthalmology Times
  5. Late Breaking Weight Loss Innovations: New Drug Therapies Shown to Offer Positive Outcomes for Obesity and Type 2 Diabetes Management PR Newswire
  6. View Full Coverage on Google News

Read original article here

Leave a Comment